Effects of the glycoprotein IIb/IIIa antagonist abciximab on thrombus formation and platelet function in cats with arterial injury

Veterinary Therapeutics

Volumn 4, Issue 1, 2003, Pages

  Bright, Janice ^a   Dowers, Kristy ^a   Powers, Barbara ^a   Tear, Marianne ^a  

^a MORRIS ANIMAL FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79251489144     PISSN: 15283593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Fox PR: Feline cardiomyopathies, in Fox PR, Sisson D, Moise NS (eds): Textbook of Canine and Feline Cardiology. Philadelphia, WB Saunders, 1999, pp 621-678.
2. Butler HC: An investigation into the relationship of an aortic embolus to posterior paralysis in the cat. J Small Anim Pract 12:141-147, 1971.
3. Schaub RG, Gates KA, Roberts RE: Inhibition of feline collateral vessel development following experimental thrombosis of the feline aorta. Am J Vet Res 43:1647-1650, 1976.
4. Olmstead ML, Butler HC: Five-hydroxytryptamine antagonists and feline aortic embolism. J Small Anim Pract 18:247-259,1977.
5. Schaub RG, Meyers KM, Sande RD: Serotonin as a factor in depression of collateral blood flow following experimental arterial thrombosis. J Lab Clin Med 90:645-653,1977.
6. Greene CE: Effects of aspirin and propranolol on feline platelet aggregation. Am J Vet Res 46:1820-1823, 1985.
7. Kittleson MD: Thromboembolic disease, in Kittleson MD, Kienle RD (eds). Small Animal Cardiovascular Medicine. St. Louis, Mosby 1998, pp 540-551.
8. Coller BS: Platelets and thrombolytic therapy. New Engl J Med 322(1):33-42, 1990.
9. Madan M, Berkowitz SC, Tcheng JE: Glycoprotein IIb/IIIa integrin blockade. Circ 98:2629-2635, 1998.
10. Gawaz M, Neumann F-J, Schomig A: Evaluation of platelet membrane glycoproteins in coronary artery disease. Circ 99:e1-e11, 1999.
11. Vernon SM: Glycoprotein IIb/IIIa receptor inhibitors. Cardiol Clin:Annu Drug Ther 3:19-36, 1999.
12. Kereiakes DJ: Oral blockade of the platelet glycoprotein IIb-IIIa receptor: Fact or fancy? Am Heart J 138:S39-S46, 1999.
13. Topol EJ: The future of antithrombotic and antiplatelet therapy for ischemic heart disease. Am Heart J 136:S66-S68, 1998.
14. Kleiman NS, Lincoff AM, Ohman EM, et al: Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: Pathophysiologic foundation and clinical findings. Am Heart J 136:S32-S42, 1998.
15. th ACVIM 19:712, 2000.
16. Parker MT, Collier LL, Kier AB, Johnson GS: Oral mucosa bleeding times of normal cats and cats with Chediak-Higashi syndrome or Hageman trait. Vet Clin Path 17:9-12.
17. Folts J: An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circ 83(suppl IV):IV3-IV14, 1991.
18. Folts JD, Schafer AI, Loscalzo J, et al: A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials. J Am Coll Cardiol 33:295-303, 1999.
19. Shapiro SS, Wilk MB: An analysis of variance test for normality (complete samples). Biometrika 52:591-611, 1965.
20. Walker GA: Common Statistical Methods for Clinical Research. Cary, NC SAS Institute, 1997.
21. Flanders JA: Feline aortic thromboembolism. Compend Contin Educ Prac Vet 8:473-484, 1986.
22. Helinski C, Ross JN: Platelet aggregation in feline cardiomyopathy. J Vet Intern Med 1:24-28, 1987.
23. Helinski C, Schaub RG, Roberts R: Improvement of collateral circulation after arterial thrombosis with indomethacin therapy. Thromb Haemost 44:69-71, 1980.
24. Schaub RG, Gates K, Roberts R: Platelet inhibitory drugs improve collateral flow after aortic thrombosis. Thromb Haemost 45:262, 1981.
25. Rawlings CA: Pulmonary arteriography and hemodynamics during feline heartworm disease: effects of aspirin. J Vet Intern Med 4:285-291, 1990.
26. Kamath S, Blann AD, Lip GYH: Platelet activation: assessment and quantification. Eur Heart J 22:1561- 1571, 2001.
27. Majerus PW, Tollefsen DM: Anticoagulant, thrombolytic, and antiplatelet drugs, in Hardman JG, Limbird LE, Goodman Gillman A (eds): Goodman & Gilman's Pharmacologic Basis of Therapeutics, ed 10. New York, McGraw-Hill, 2001, pp 1519-1538.
28. Tablin F, Johnsrude JD, Walker NJ: Evaluation of glycoprotein Ib expression on feline platelets. Am J Vet Res 62:195-201, 2001.
29. Darbes J, Colbatzky F, Minkus G, et al: Demonstration of feline and canine platelet glycoproteins by immuno- and lectin histochemistry. Histochem 100:83-91, 1993.
30. Bright JM, Dowers K, Hellyer P: [letter]. J Vet Intern Med 16:f, 2002.
31. Harrington RA, Kleiman NS, Granger CB, et al: Relation between inhibition of platelet aggregation and clinical outcomes. Am Heart J 136:S43-S50, 1998.
32. Topol EJ, Moliterno DJ, Herrmann HC, et al: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344(25):1888-1894, 2001.
33. Peerschke EI: The platelet fibrinogen receptor. Semin Hematol 22:241-259, 1985.
34. van Willigen G, Akkerman J: Regulation of glycoprotein IIb/IIIa exposure on platelets stimulated with Ã-thrombin. Blood 72:82-90, 1992.
35. Wencel-Drake JD, Plow EF, Zimmerman TS, et al: Immunofluorescent localization of adhesive glycoprotein in resting and thrombin-stimulated platelets. Am J Pathol 115:156-164, 1984.
36. Kleiman NS, Raizner AE, Jordan R, et al: Differential inhibition of platelet aggregation induced by ADP or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GP IIb/IIIa receptors. J Am Coll Cardiol 26:1665-1671, 1995.
37. Coller BS, Folts JD, Smith SR, et al: Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GP IIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of AP IIb/IIIa receptors. Circ 80:1766-1774, 1989.
38. Wu KK, Willerson JT: Monitoring platelet function in glycoprotein IIb/IIIa inhibitor therapy. Circ 103:2528-2530, 2001.
39. Smith JW, Steinhubl SR, Lincoff AM, et al: Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circ 99:620-625, 1999.
40. Steinhubl SR, Talley JD, Braden GA, et al: Point-of-care measured platelet inhibition correlates with the risk of adverse cardiac event following percutaneous coronary intervention. Circ 103:2572-2578, 2001.
41. Osende JI, Fuster V, Leu EI, et al: Testing platelet activation with a shear-dependent platelet function test vs. aggregation based tests. Circ 103:1488-1491, 2001.
42. von dem Borne PA, Meijers JCM, Bouma BN: Effect of heparin on the activation of factor XI by fibrin-bound thrombin. Thromb Haemost 76:347-353, 1996.
43. Bates SM, Weitz JI: Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol 82:12P-18P, 1998.
44. Blazing MA, de Lemos JA, Dyke CK, et al: The A-to-Z trial: methods and rationale for a single trial investigatin combined use of low-molecular weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive siimvastatin therapy. Am Heart J 142:211-217, 2001.
45. Cohen M, Theroux P, Weber S, et al: Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 71:273-281, 1999.
46. Cohen M, Theroux P, Frey MM, et al: Anti-thrombotic combination using tirofiban and enoxaparin: The acute II study [abstract]. Circ 102:11826, 2000.
47. Antman EM: The search for replacements for unfractionated heparin. Circ 103:2310-2314, 2001.
48. Califf RM: Combination therapy for acute myocardial infarction: Fibrinolytic therapy and glycoprotein IIb/IIIa inhibition. Am Heart J 139:S33-S37, 2000.
49. Gold HK, Coller BS, Yasuda T, et al: Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circ 77:670-677, 1988.